GLP1R and Parkinson disease: A recent study showed that blocking of microglial-mediated astrocyte conversion with glucagon-like peptide-1 receptors (GLP1R) agonist, NLY01, exhibited protective effects in this PD model and successfully protected against dopaminergic neuronal loss and behavioural deficits [101].